{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:28:41Z","timestamp":1762522121609,"version":"build-2065373602"},"reference-count":45,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,1,19]],"date-time":"2018-01-19T00:00:00Z","timestamp":1516320000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008287","name":"Science and Technology Directorate of the U.S. Department of Homeland Security","doi-asserted-by":"publisher","award":["HSHQPD-07-X-00003","HSHQDC-14-F-00035","GS-23F-80006H","HSHQDC-8-C-00011"],"award-info":[{"award-number":["HSHQPD-07-X-00003","HSHQDC-14-F-00035","GS-23F-80006H","HSHQDC-8-C-00011"]}],"id":[{"id":"10.13039\/100008287","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Benchmark Biolabs"},{"DOI":"10.13039\/100000015","name":"U.S. Department of Energy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000015","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000180","name":"DHS S&T","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000180","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000015","name":"DOE","doi-asserted-by":"publisher","award":["DE-AC05-06OR23100"],"award-info":[{"award-number":["DE-AC05-06OR23100"]}],"id":[{"id":"10.13039\/100000015","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008287","name":"DHS S&T","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008287","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.vaccine.2018.01.026","type":"journal-article","created":{"date-parts":[[2018,1,20]],"date-time":"2018-01-20T17:18:42Z","timestamp":1516468722000},"page":"1078-1084","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Use of ENABL\u00ae adjuvant to increase the potency of an adenovirus-vectored foot-and-mouth disease virus serotype A subunit vaccine"],"prefix":"10.1016","volume":"36","author":[{"given":"Jos\u00e9","family":"Barrera","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Schutta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melia","family":"Pisano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marvin J.","family":"Grubman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Brake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara J.","family":"Kamicker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Femi","family":"Olutunmbi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damodar","family":"Ettyreddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas E.","family":"Brough","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryan T.","family":"Butman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John G.","family":"Neilan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3\u20134","key":"10.1016\/j.vaccine.2018.01.026_b0005","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.prevetmed.2013.07.013","article-title":"The economic impacts of foot and mouth disease - what are they, how big are they and where do they occur?","volume":"112","author":"Knight-Jones","year":"2013","journal-title":"Prev Veter Med"},{"key":"10.1016\/j.vaccine.2018.01.026_b0010","unstructured":"OIE. Foot and mouth disease 2013. Available from: <http:\/\/www.oie.int\/fileadmin\/Home\/eng\/Animal_Health_in_the_World\/docs\/pdf\/Disease_cards\/FOOT_AND_MOUTH_DISEASE.pdf> [accessed 08 January 2018]."},{"issue":"1","key":"10.1016\/j.vaccine.2018.01.026_b0015","first-page":"63","article-title":"Combining livestock trade patterns with phylogenetics to help understand the spread of foot and mouth disease in sub-Saharan Africa, the Middle East and Southeast Asia","volume":"30","author":"Di Nardo","year":"2011","journal-title":"Revue scientifique et technique (International Office of Epizootics)"},{"issue":"4","key":"10.1016\/j.vaccine.2018.01.026_b0020","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1292\/jvms.11-0271","article-title":"The 2010 foot-and-mouth disease epidemic in Japan","volume":"74","author":"Muroga","year":"2012","journal-title":"J Veter Med Sci\/Jpn Soc Veter Sci"},{"issue":"3","key":"10.1016\/j.vaccine.2018.01.026_b0025","doi-asserted-by":"crossref","first-page":"675","DOI":"10.20506\/rst.21.3.1353","article-title":"Economic costs of the foot and mouth disease outbreak in the United Kingdom in 2001","volume":"21","author":"Thompson","year":"2002","journal-title":"Revue Sci Tech (International Office of Epizootics)"},{"issue":"3","key":"10.1016\/j.vaccine.2018.01.026_b0030","doi-asserted-by":"crossref","first-page":"577","DOI":"10.20506\/rst.21.3.1361","article-title":"Development and performance of inactivated vaccines against foot and mouth disease","volume":"21","author":"Barteling","year":"2002","journal-title":"Revue Sci Tech (Int Off Epizootics)"},{"issue":"2","key":"10.1016\/j.vaccine.2018.01.026_b0035","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1006\/viro.1999.9940","article-title":"Development of replication-defective adenovirus serotype 5 containing the capsid and 3C protease coding regions of foot-and-mouth disease virus as a vaccine candidate","volume":"263","author":"Mayr","year":"1999","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2018.01.026_b0040","first-page":"123","article-title":"Human adenovirus-vectored foot-and-mouth disease vaccines: establishment of a vaccine product profile through in vitro testing","volume":"134","author":"Brake","year":"2012","journal-title":"Dev Biol"},{"key":"10.1016\/j.vaccine.2018.01.026_b0045","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2217\/fvl.09.68","article-title":"Adenovirus serotype-5 vectored foot-and-mouth disease subunit vaccines: the first decade","volume":"5","author":"Grubman","year":"2010","journal-title":"Future Virol"},{"issue":"15\u201316","key":"10.1016\/j.vaccine.2018.01.026_b0050","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1016\/S0264-410X(00)00384-4","article-title":"Immune responses and protection against foot-and-mouth disease virus (FMDV) challenge in swine vaccinated with adenovirus-FMDV constructs","volume":"19","author":"Mayr","year":"2001","journal-title":"Vaccine"},{"issue":"11\u201312","key":"10.1016\/j.vaccine.2018.01.026_b0055","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1016\/S0264-410X(01)00483-2","article-title":"Early protection against homologous challenge after a single dose of replication-defective human adenovirus type 5 expressing capsid proteins of foot-and-mouth disease virus (FMDV) strain A24","volume":"20","author":"Moraes","year":"2002","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2018.01.026_b0060","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.virol.2005.04.014","article-title":"Rapid protection of cattle from direct challenge with foot-and-mouth disease virus (FMDV) by a single inoculation with an adenovirus-vectored FMDV subunit vaccine","volume":"337","author":"Pacheco","year":"2005","journal-title":"Virology"},{"issue":"27","key":"10.1016\/j.vaccine.2018.01.026_b0065","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1016\/j.vaccine.2015.12.018","article-title":"Multiple efficacy studies of an adenovirus-vectored foot-and-mouth disease virus serotype A24 subunit vaccine in cattle using homologous challenge","volume":"34","author":"Schutta","year":"2016","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.vaccine.2018.01.026_b0070","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1016\/j.vaccine.2011.12.082","article-title":"Early detection and visualization of human adenovirus serotype 5-viral vectors carrying foot-and-mouth disease virus or luciferase transgenes in cell lines and bovine tissues","volume":"30","author":"Montiel","year":"2012","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.vaccine.2018.01.026_b0075","doi-asserted-by":"crossref","first-page":"6497","DOI":"10.1128\/jvi.70.9.6497-6501.1996","article-title":"A gene transfer vector-cell line system for complete functional complementation of adenovirus early regions E1 and E4","volume":"70","author":"Brough","year":"1996","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.01.026_b0080","unstructured":"OIE. Foot and mouth disease. Chapter 2.1.5. Paris, France: World Organisation for Animal Health; 2012. Available from: <http:\/\/www.oie.int\/fileadmin\/Home\/eng\/Health_standards\/tahm\/2008\/pdf\/2.01.05_FMD.pdf> [accessed 08 January 2018]."},{"issue":"6","key":"10.1016\/j.vaccine.2018.01.026_b0085","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1128\/JCM.03370-12","article-title":"A continuous bovine kidney cell line constitutively expressing bovine alphavbeta6 integrin has increased susceptibility to foot-and-mouth disease virus","volume":"51","author":"LaRocco","year":"2013","journal-title":"J Clin Microbiol"},{"issue":"2","key":"10.1016\/j.vaccine.2018.01.026_b0090","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1128\/JCM.03220-14","article-title":"Correction for LaRocco et al., a continuous bovine kidney cell line constitutively expressing bovine alphaVbeta6 Integrin has increased susceptibility to foot-and-mouth disease virus","volume":"53","author":"LaRocco","year":"2015","journal-title":"J Clin Microbiol"},{"issue":"11","key":"10.1016\/j.vaccine.2018.01.026_b0095","doi-asserted-by":"crossref","first-page":"7179","DOI":"10.4049\/jimmunol.174.11.7179","article-title":"Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein","volume":"174","author":"Sumida","year":"2005","journal-title":"J Immunol (Baltimore, Md: 1950)."},{"issue":"11","key":"10.1016\/j.vaccine.2018.01.026_b0100","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.2460\/javma.2002.220.1636","article-title":"Use of a portable real-time reverse transcriptase-polymerase chain reaction assay for rapid detection of foot-and-mouth disease virus","volume":"220","author":"Callahan","year":"2002","journal-title":"J Am Veter Med Assoc"},{"key":"10.1016\/j.vaccine.2018.01.026_b0105","article-title":"Safety profile of a replication-deficient human adenovirus-vectored foot-and-mouth disease virus serotype A24 subunit vaccine in cattle","author":"Barrera","year":"2017","journal-title":"Transboundary Emerg Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2018.01.026_b0110","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1128\/CVI.00426-15","article-title":"Evaluation of a fiber-modified adenovirus vector vaccine against foot-and-mouth disease in cattle","volume":"23","author":"Medina","year":"2015","journal-title":"Clin Vaccine Immunol: CVI"},{"key":"10.1016\/j.vaccine.2018.01.026_b0115","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.vetmic.2017.03.019","article-title":"Recombinant human adenovirus-5 expressing capsid proteins of Indian vaccine strains of foot-and-mouth disease virus elicits effective antibody response in cattle","volume":"203","author":"Sreenivasa","year":"2017","journal-title":"Veter Microbiol"},{"issue":"50","key":"10.1016\/j.vaccine.2018.01.026_b0120","doi-asserted-by":"crossref","first-page":"5775","DOI":"10.1016\/j.vaccine.2005.07.043","article-title":"Vaccination against foot-and-mouth disease virus confers complete clinical protection in 7 days and partial protection in 4 days: use in emergency outbreak response","volume":"23","author":"Golde","year":"2005","journal-title":"Vaccine"},{"issue":"13","key":"10.1016\/j.vaccine.2018.01.026_b0125","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.vaccine.2008.01.038","article-title":"High potency vaccines induce protection against heterologous challenge with foot-and-mouth disease virus","volume":"26","author":"Brehm","year":"2008","journal-title":"Vaccine"},{"issue":"33","key":"10.1016\/j.vaccine.2018.01.026_b0130","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1016\/j.vaccine.2013.05.078","article-title":"Montanide ISA 201 adjuvanted FMD vaccine induces improved immune responses and protection in cattle","volume":"31","author":"Dar","year":"2013","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2018.01.026_b0135","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1016\/j.vaccine.2010.12.127","article-title":"Evaluation of cross-protection between O1 Manisa and O1 Campos in cattle vaccinated with foot-and-mouth disease virus vaccine incorporating different payloads of inactivated O1 Manisa antigen","volume":"29","author":"Nagendrakumar","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.01.026_b0140","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.virol.2014.08.012","article-title":"Poly ICLC increases the potency of a replication-defective human adenovirus vectored foot-and-mouth disease vaccine","volume":"468\u2013470","author":"Diaz-San Segundo","year":"2014","journal-title":"Virology"},{"issue":"3","key":"10.1016\/j.vaccine.2018.01.026_b0145","doi-asserted-by":"crossref","first-page":"589","DOI":"10.20506\/rst.21.3.1360","article-title":"Prospects, including time-frames, for improved foot and mouth disease vaccines","volume":"21","author":"Grubman","year":"2002","journal-title":"Revue Sci Tech (International Office of Epizootics)"},{"key":"10.1016\/j.vaccine.2018.01.026_b0150","unstructured":"Mittal SK, Tikoo SK, Van Donkersgoed J, Beskorwayne T, Godson DL, Babiuk LA. Experimental inoculation of heifers with bovine adenovirus type 3. Can J Veter Res = Revue canadienne de recherche veterinaire 1999;63(2):153\u20136."},{"issue":"1","key":"10.1016\/j.vaccine.2018.01.026_b0155","doi-asserted-by":"crossref","first-page":"e55228","DOI":"10.1371\/journal.pone.0055228","article-title":"Engineering foot-and-mouth disease viruses with improved growth properties for vaccine development","volume":"8","author":"Zheng","year":"2013","journal-title":"PloS One"},{"issue":"1\u20132","key":"10.1016\/j.vaccine.2018.01.026_b0160","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.vetmic.2007.10.003","article-title":"Cedivac-FMD can be used according to a marker vaccine principle","volume":"128","author":"Chenard","year":"2008","journal-title":"Veter Microbiol"},{"issue":"47\u201348","key":"10.1016\/j.vaccine.2018.01.026_b0165","doi-asserted-by":"crossref","first-page":"6966","DOI":"10.1016\/j.vaccine.2006.04.050","article-title":"Comparative evaluation of six ELISAs for the detection of antibodies to the non-structural proteins of foot-and-mouth disease virus","volume":"24","author":"Brocchi","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.01.026_b0170","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1746-6148-2-30","article-title":"Evaluation of three 3ABC ELISAs for foot-and-mouth disease non-structural antibodies using latent class analysis","volume":"2","author":"Bronsvoort","year":"2006","journal-title":"BMC Vet Res"},{"issue":"1","key":"10.1016\/j.vaccine.2018.01.026_b0175","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jviromet.2008.04.004","article-title":"Development and characterization of a bovine serum evaluation panel as a standard for immunoassays based on detection of antibodies against foot-and-mouth disease viral non-capsid proteins","volume":"151","author":"Campos Rde","year":"2008","journal-title":"J Virol Methods"},{"issue":"42\u201343","key":"10.1016\/j.vaccine.2018.01.026_b0180","doi-asserted-by":"crossref","first-page":"6503","DOI":"10.1016\/j.vaccine.2006.06.032","article-title":"Application of non-structural protein antibody tests in substantiating freedom from foot-and-mouth disease virus infection after emergency vaccination of cattle","volume":"24","author":"Paton","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.01.026_b0185","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3389\/fvets.2016.00105","article-title":"Transmission of foot-and-mouth disease virus during the incubation period in pigs","volume":"3","author":"Stenfeldt","year":"2016","journal-title":"Front Vet Sci"},{"issue":"9","key":"10.1016\/j.vaccine.2018.01.026_b0190","doi-asserted-by":"crossref","first-page":"e106859","DOI":"10.1371\/journal.pone.0106859","article-title":"Early events in the pathogenesis of foot-and-mouth disease in pigs; identification of oropharyngeal tonsils as sites of primary and sustained viral replication","volume":"9","author":"Stenfeldt","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.vaccine.2018.01.026_b0195","unstructured":"Doel TR. Potency assessment of inactivated viral vaccines. In: Vaccine manual. The production and quality control of veterinary vaccines for use in developing countries. Mowat N, Rweyemamu, M., editor. Rome, Italy: Food and Agriculture Organization of the United Nations; 1997."},{"issue":"1","key":"10.1016\/j.vaccine.2018.01.026_b0200","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0168-1702(02)00261-7","article-title":"FMD vaccines","volume":"91","author":"Doel","year":"2003","journal-title":"Virus Res"},{"issue":"11","key":"10.1016\/j.vaccine.2018.01.026_b0205","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1586\/14760584.2014.963562","article-title":"Adjuvants for foot-and-mouth disease virus vaccines: recent progress","volume":"13","author":"Cao","year":"2014","journal-title":"Expert Rev Vaccines"},{"issue":"13","key":"10.1016\/j.vaccine.2018.01.026_b0210","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0264-410X(96)00055-2","article-title":"International bank for foot-and-mouth disease vaccine: assessment of Montanide ISA 25 and ISA 206, two commercially available oil adjuvants","volume":"14","author":"Barnett","year":"1996","journal-title":"Vaccine"},{"issue":"40","key":"10.1016\/j.vaccine.2018.01.026_b0215","doi-asserted-by":"crossref","first-page":"5221","DOI":"10.1016\/j.vaccine.2014.07.040","article-title":"Enhanced immune responses of foot-and-mouth disease vaccine using new oil\/gel adjuvant mixtures in pigs and goats","volume":"32","author":"Park","year":"2014","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2018.01.026_b0220","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.vaccine.2014.12.008","article-title":"Protective immune response to liposome adjuvanted high potency foot-and-mouth disease vaccine in Indian cattle","volume":"33","author":"Saravanan","year":"2015","journal-title":"Vaccine"},{"issue":"19","key":"10.1016\/j.vaccine.2018.01.026_b0225","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1016\/j.vaccine.2014.02.061","article-title":"Early protection against foot-and-mouth disease virus in cattle using an inactivated vaccine formulated with Montanide ESSAI IMS D 12802 VG PR adjuvant","volume":"32","author":"Quattrocchi","year":"2014","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18300604?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18300604?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:24:44Z","timestamp":1759400684000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18300604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":45,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["S0264410X18300604"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.01.026","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of ENABL\u00ae adjuvant to increase the potency of an adenovirus-vectored foot-and-mouth disease virus serotype A subunit vaccine","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.01.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}